New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial
NCT ID NCT07660055
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatment is safe, what dose works best, and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radioligand therapy (177Lu-DWJ155) and imaging agent (68Ga-DWJ155)
What this could lead to
If successful, this could lead to a new targeted treatment option for several hard-to-treat solid tumors.
What could go wrong
This is an early Phase 1 trial, so safety and dosing are still being figured out. It may not shrink tumors or work for all cancer types tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Novartis Investigative Site
RECRUITINGKashiwa, Chiba, 277-8577, Japan